Product Pipeline

FIRST FOCUS – Prostate Cancer

Lazure has chosen the treatment of early-stage, localized prostate cancer as its first CE Mark and FDA approved indication for use. The safe and effective treatment of early stage prostate cancer is a major need particularly suited to the LDAC device.

While progress is evident in the early detection and treatment of this disease, currently used therapies are not always effective at eliminating cancer and carry high rates of long term, unwanted sexual and urinary side effects, such as incontinence and erectile dysfunction. For example, according to a published report in The Journal of The American Medical Association, 59.9% of men who were potent before radical prostatectomy were impotent 18 months after the procedure and 41.9% reported that their sexual performance was a moderate to large problem at 18 or more months post-surgery. The study conclusions “suggest that radical prostatectomy is associated with significant erectile dysfunction and some decline in urinary function.”

Serious side effects from current prostate cancer treatment methods are due to a lack of treatment selectivity that damages critical nerves and other tissues.  These current methods include surgery, external beam radiation (EBRT), brachytherapy, cryotherapy and high intensity focused ultrasound (HIFU)

As noted in the December 11, 2009 FDA General Issues Panel Meeting on Clinical Studies of Devices intended for the Treatment of Localized Prostate Cancer:

Given the morbidity associated with the current therapeutic options, coupled with the realization that many men diagnosed today with prostate cancer will not die of the cancer, the current treatment options are increasingly being viewed as less acceptable.  As a result, patients with localized prostate cancer are confronted with the difficult decision to pursue treatments, which can cause significant and lasting side effects for a disease, which, in most cases, will not impact them clinically in their lifetime.  This situation has lead to the view that there appears to be an imbalance between the risks of localized prostate cancer (i.e., progression/disease specific mortality) and the harm of treatment, leading patients (and some in the clinical community) to view the treatment as worse than the disease.

Therefore, patient groups and the clinical community are expressing a need for new treatment options that offer definitive therapy for localized prostate cancer with low morbidity.”


Our preclinical testing, as well as published literature, supports LaZure’s view that its technology can be effective in treating other prevalent forms of cancer. While the Company is currently focused exclusively on its prostate cancer application, in the future it plans to develop devices and procedures for treating other cancers using its LDAC technology. These possible cancer applications include:

  • Breast Cancer
  • Lung Cancer
  • Colon Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Melanoma
  • Brain Cancer